CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES

被引：0

作者：

de Botton, S. ^{[1
]}

Pollyea, D. A. ^{[2
]}

Stein, E. M. ^{[3
]}

DiNardo, C. ^{[4
]}

Fathi, A. T. ^{[5
]}

Roboz, G. J. ^{[6
]}

Collins, R. ^{[7
]}

Swords, R. T. ^{[8
]}

Flinn, I. ^{[9
]}

Altman, J. K. ^{[10
]}

Tallman, M. S. ^{[3
]}

Kantarjian, H. ^{[4
]}

Colby, K. ^{[11
]}

Fan, B. ^{[11
]}

Goldwasser, M. ^{[11
]}

Prahl, M. ^{[11
]}

Agresta, S. ^{[11
]}

Stone, R. M. ^{[12
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Univ Colorado, Ctr Canc, Aurora, CO USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[8] Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Sarah Cannon Res Inst, Nashville, TN USA

[10] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[11] Agios Pharmaceut, Cambridge, MA 02139 USA

[12] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P563

引用

页码：214 / 215

页数：2

共 50 条

[31] AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
Hansen, Erica
Quivoron, Cyril
Straley, Kim
Lemieux, Rene M.
Popovici-Muller, Janeta
Sadrzadeh, Hossein
Fathi, Amir T.
Gliser, Camelia
David, Muriel
Saada, Veronique
Micol, Jean-Baptiste
Bernard, Olivier
Dorsch, Marion
Yang, Hua
Su, Michael
Agresta, Sam
de Botton, Stephane
Penard-Lacronique, Virginie
Yen, Katharine
BLOOD, 2014, 124 (21)
[32] Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.
Lowery, Maeve Aine
Abou-Alfa, Ghassan K.
Burris, Howard A.
Janku, Filip
Shroff, Rachna T.
Cleary, James M.
Azad, Nilofer Saba
Goyal, Lipika
Maher, Elizabeth A.
Gore, Lia
Hollebecque, Antoine
Beeram, Muralidhar
Trent, Jonathan C.
Jiang, Liewen
Ishii, Yuko
Auer, Julia
Gliser, Camelia
Agresta, Samuel V.
Pandya, Shuchi Sumant
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[33] High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine
Daigle, Scott R.
Choe, Sung
Quek, Lynn
DiNardo, Courtney D.
Stein, Anthony
Stein, Eytan M.
Fathi, Amir T.
Frankfurt, Olga
Schuh, Andre C.
Kantarjian, Hagop M.
Zhang, Vickie
Winkler, Thomas
Vyas, Paresh
Wu, Bin
BLOOD, 2019, 134
[34] Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies
Jiang, Xuemin
Wada, Russ
Poland, Bill
Kleijn, Huub Jan
Fan, Bin
Liu, Guowen
Liu, Hua
Kapsalis, Stephanie
Yang, Hua
Le, Kha
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (03): : 942 - 953
[35] Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
DiNardo, C.
Stein, A.
Stein, E.
Fathi, A.
Frankfurt, O.
Schuh, A.
Doehner, H.
Martinelli, G.
Patel, P.
Raffoux, E.
Tan, P.
Zeidan, A.
de Botton, S.
Kantarjian, H.
Stone, R.
Lam, D.
Wang, X.
Gong, J.
Kapsalis, S.
Hickman, D.
Zhang, V.
Winkler, T.
Wu, B.
Vyas, P.
ANNALS OF HEMATOLOGY, 2019, 98 : S40 - S41
[36] Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model
Yen, Katharine
Chopra, Vivek S.
Tobin, Erica
Avanzino, Brian
Mavrommatis, Konstantinos
DiMartino, Jorge
MacBeth, Kyle J.
CANCER RESEARCH, 2018, 78 (13)
[37] Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies
Fan, Bin
Chen, Yue
Wang, Fang
Yen, Katharine
Utley, Luke
Almon, Caroline
Biller, Scott
Agresta, Sam
Yang, Hua
BLOOD, 2014, 124 (21)
[38] Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax plus /- azacitidine in IDH1-mutated hematologic malignancies.
Lachowiez, Curtis Andrew
Borthakur, Gautam
Loghavi, Sanam
Zeng, Zhihong
Kadia, Tapan M.
Masarova, Lucia
Takahashi, Koichi
Tippett, George Dono
Naqvi, Kiran
Bose, Prithviraj
Jabbour, Elias
Ravandi, Farhad
Daver, Naval Guastad
Garcia-Manero, Guillermo
Stoilova, Bilyana
Vyas, Paresh
Kantarjian, Hagop M.
Konopleva, Marina
Dinardo, Courtney Denton
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[39] Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial
Gao, Yue
Fan, Bin
Le, Kha
Manyak, Erika
Yang, Hua
Yen, Katherine
Agresta, Sam
Attar, Eyal C.
Chen, Jian
Xu, Qiang
Tosolini, Alessandra
Mei, Jay M.
Thakurta, Anjan
Knight, Robert D.
Li, Yan
BLOOD, 2015, 126 (23)
[40] A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.
Pauff, James Michael
Papadopoulos, Kyriakos P.
Janku, Filip
Turk, Anita Ahmed
Goyal, Lipika
Shroff, Rachna T.
Shimizu, Toshio
Ikeda, Masafumi
Azad, Nilofer Saba
Cleary, James M.
Peters, Mary Linton Bounetheau
Borad, Mitesh J.
Jaeckle, Kurt A.
Kizilbash, Sani Haider
Tupper, Rebecca
Furin, Carrie E.
Hanley, Matthew P.
Hill, Elizabeth Goodwin
Xu Xiaojian
Harding, James J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

← 1 2 3 4 5 →